A randomized controlled trial comparing romosozumab and denosumab in elderly women with primary osteoporosis and knee osteoarthritis.

ABSTRACT: We compared the efficacy of romosozumab and denosumab in elderly women with primary osteoporosis and knee osteoarthritis in a randomized controlled trial. A total of 112 participants aged 75-90 years were randomized equally into the romosozumab and denosumab groups. Among these, 49 and 52 participants, respectively, who received their initial dose were included in the analysis. The primary outcome was change in lumbar spine (LS)-bone mineral density (BMD) at 12 months in the romosozumab group versus the denosumab group. Secondary outcomes were changes in knee osteophyte development, patient-reported outcomes (PROs), and the incidence of serious adverse events. Mean age of participants was 80.9 years. There was no difference in baseline LS-BMD between the two groups, with a T-score of -2.6.

SUBMITTER: Sobue Y 

PROVIDER: S-EPMC12214567 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature